Biosynth has announced the appointment of Matt Gunnison as its new Chief Executive Officer and member of the Board of Directors, effective immediately. Kieran Murphy has also been named Chairman, marking a leadership transition poised to guide the company’s continued growth in the life sciences sector.
Matt Gunnison succeeds Urs Spitz, who led Biosynth through a period of significant growth and will remain on the Board of Directors. “We are grateful to Urs for his contributions in shaping Biosynth into the innovative company it is today,” said Kugan Sathiyanandarajah, Partner at KKR and Head of Europe for KKR’s Health Care Strategic Growth strategy. “We’re excited to welcome Matt as CEO, whose vision and experience will be pivotal in driving the next chapter of Biosynth’s growth.”
Expressing enthusiasm for his new role, Gunnison said, “I’m thrilled to join Biosynth at such an exciting time. The company has built a solid foundation under Urs’s leadership, and I look forward to working with the talented team to drive further growth and innovation.”
As Chairman, Kieran Murphy shared his optimism: “It’s an honor to step into this role. I look forward to collaborating with Matt and the team to support Biosynth’s leadership in life sciences. We are well-positioned for continued success.”
Reflecting on the company’s achievements, Urs Spitz congratulated the new leadership team and expressed confidence in Biosynth’s future.
Matt Gunnison joins Biosynth from Gamma Biosciences, a life sciences investment platform he co-founded with KKR, where he led a portfolio focused on biopharmaceutical manufacturing. Previously, he held leadership roles at GE Healthcare. Kieran Murphy, formerly President and CEO of GE Healthcare, will transition to Biosynth from Gamma Biosciences, bringing decades of experience in life sciences.
Eric Simpson, previously Vice President at Gamma Biosciences, will also join Biosynth as Head of Corporate Development.
About Biosynth
Biosynth supplies essential materials for life sciences, supporting pharmaceutical and diagnostic sectors with research, manufacturing, and distribution capabilities. With a broad portfolio of over a million products and advanced manufacturing services in complex chemicals, peptides, and biologics, Biosynth is based in Staad, Switzerland, and backed by investors like KKR, Ampersand Capital Partners, and management.
About KKR
KKR is a global investment firm providing alternative asset management and insurance solutions. With a focus on private equity, credit, real assets, and hedge funds, KKR aims to foster growth in its portfolio companies and communities. For more information, visit www.kkr.com.
About Ampersand
Founded in 1988, Ampersand Capital Partners is a private equity firm specializing in healthcare investments. With offices in Boston and Amsterdam, Ampersand partners with management teams to drive value in healthcare sectors. For more, visit ampersandcapital.com.
